Sugi Predict

Sugi Predict / Compounds / SCHEMBL8360658

SCHEMBL8360658

SCHEMBL8360658

CC(C)S(=O)(=O)NC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ GRIA1 P42261 3/20 0.39
▸ GRIA4 P48058 3/20 0.33
▸ POLB P06746 1/20 0.31
▸ PARG Q86W56 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.30
▸ MEN1 O00255 1/20 0.30
▸ NPC1 O15118 1/20 0.30
▸ LMNA P02545 1/20 0.30
▸ MAPT P10636 1/20 0.30
▸ HPGD P15428 1/20 0.30
▸ RAB9A P51151 1/20 0.30
▸ KMT2A Q03164 1/20 0.30
▸ SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23872667 0.78 GRIA1 (0.36) GRIA1GRIA4
SCHEMBL19103690 0.78 — —
SCHEMBL21671808 0.74 GRIA1 (0.37) GRIA1
SCHEMBL19115401 0.74 — —
SCHEMBL26144753 0.74 GRIA1 (0.33) GRIA1GRIA4
SCHEMBL24846538 0.74 GRIA1 (0.33) GRIA1GRIA4
SCHEMBL8097727 0.74 POLB (0.31) POLB
SCHEMBL18595757 0.74 GRIA1 (0.38) GRIA1GRIA4PARG
SCHEMBL23872856 0.72 GRIA1 (0.37) GRIA1GRIA4
SCHEMBL23872681 0.72 GRIA1 (0.37) GRIA1GRIA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024044778-A2 NOVEL MODULATORS OF FSHR AND USES THEREOF CELMATIX INC. (US) 2024-02-29 — — WO disclosed
WO-2024044757-A1 AMINOPYRIMIDINE AND AMINOTRIAZINE DERIVATIVES AS MYC PROTEIN MODULATORS Sanford Burnham Prebys Medical Discovery Institute (US) 2024-02-29 — — WO disclosed
WO-2024035950-A1 INHIBITORS OF KIF18A AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2024-02-15 — — WO disclosed
US-20230382889-A1 COMPOUNDS FOR INHIBITING KIF18A VOLASTRA THERAPEUTICS, INC. (US) 2023-11-30 — — US disclosed
US-20230382889-A1 COMPOUNDS FOR INHIBITING KIF18A VOLASTRA THERAPEUTICS, INC. (US) 2023-11-30 — — US disclosed
US-20230357199-A1 ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS ACHILLION PHARMACEUTICALS, INC. 2023-11-09 — — US disclosed
WO-2023212240-A1 COMPOUNDS FOR INHIBITING KIF18A VOLASTRA THERAPEUTICS, INC. (US) 2023-11-02 — — WO disclosed
WO-2023159303-A1 MYC-MAX INHIBITORS FOR CANCER TREATMENT, METHODS AND USES ASSOCIATED THEREWITH THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2023-08-31 — — WO disclosed
US-11708351-B2 Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders ACHILLION PHARMACEUTICALS, INC. (US) 2023-07-25 — — US disclosed
WO-2023078271-A1 AROMATIC COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF 上海旭成医药科技有限公司 2023-05-11 — — WO disclosed
US-7511063-B2 High affinity quinoline-based kinase ligands SCHERING CORPORATION (US) 2009-03-31 — — US disclosed
US-20080275032-A1 Pyridazinone compounds ANADYS PHARMACEUTICALS, INC. 2008-11-06 — — US disclosed
US-20080275032-A1 Pyridazinone compounds ANADYS PHARMACEUTICALS, INC. 2008-11-06 — — US disclosed
WO-2008082725-A1 PYRIDAZINONE COMPOUNDS ANADYS PHARMACEUTICALS, INC. (US) 2008-07-10 — — WO disclosed
US-20080045568-A1 Novel high affinity quinoline-based kinase ligands SCHERING CORPORATION 2008-02-21 — — US disclosed
US-5981595-A LOWERS BLOOD CHOLESTEROL LEVELS WARNER-LAMBERT COMPANY (US) 1999-11-09 — — US disclosed
US-5834404-A Substituted bicycloheptanedione derivative and herbicide NIPPON SODA CO., LTD. (JP) 1998-11-10 — — US disclosed
EP-0791572-A1 SUBSTITUTED BICYCLOHEPTANEDIONE DERIVATIVE AND HERBICIDE NIPPON SODA CO., LTD. (JP) 1997-08-27 — — EP disclosed
US-5254589-A Anticholesterol agent WARNER-LAMBERT COMPANY (US) 1993-10-19 — — US disclosed
WO-1993008161-A1 SULFONYL UREA AND CARBAMATE ACAT INHIBITORS WARNER-LAMBERT COMPANY (US) 1993-04-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382889-A1 COMPOUNDS FOR INHIBITING KIF18A KIF18A, KIF18B, KIF2C GRIA1 3770/4885GRIA4 4054/4885POLB 581/4885
US-11708351-B2 Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders CFD, TFPI, CFH GRIA1 4470/4885GRIA4 4191/4885POLB 3304/4885
US-20230357199-A1 ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS CFD, TFPI, CFH GRIA1 4470/4885GRIA4 4191/4885POLB 3304/4885
US-20080045568-A1 Novel high affinity quinoline-based kinase ligands CDKL2, CDK2, CDKL1 GRIA1 1293/4885GRIA4 1958/4885POLB 710/4885
US-20080275032-A1 Pyridazinone compounds HAVCR2, PLPBP, CYP3A43 GRIA1 4617/4885GRIA4 4542/4885POLB 772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.